Ipilimumab/nivolumab/pembrolizumabGastroparesis: 3 case reports

被引：0

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1871卷 / 1期

关键词：

D O I：

10.1007/s40278-021-01735-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：216 / 216

相关论文

共 50 条

[21] Ipilimumab/nivolumab/pembrolizumabNeuromuscular disorders/pneumonitis: 3 case reports [J].

Reactions Weekly, 2021, 1851 (1) :195-195

[22] Ipilimumab/nivolumab/pembrolizumabVitiligo like depigmentation: 3 case reports [J].

Reactions Weekly, 2019, 1765 (1) :204-204

[23] Ipilimumab/nivolumab/pembrolizumabMyocarditis: 4 case reports [J].

Reactions Weekly, 2021, 1837 (1) :367-367

[24] Ipilimumab/nivolumab/pembrolizumabPneumonitis: 2 case reports [J].

Reactions Weekly, 2022, 1917 (1) :327-327

[25] Ipilimumab/nivolumab/pembrolizumabEncephalopathy: 14 case reports [J].

Reactions Weekly, 2021, 1860 (1) :205-206

[26] Ipilimumab/nivolumab/pembrolizumabTrabeculitis: 2 case reports [J].

Reactions Weekly, 2022, 1933 (1) :253-253

[27] Ipilimumab/nivolumab/pembrolizumabHepatitis: 7 case reports [J].

Reactions Weekly, 2022, 1922 (1) :341-341

[28] Ipilimumab/nivolumab/pembrolizumabPneumonitis: 4 case reports [J].

Reactions Weekly, 2020, 1794 (1) :131-131

[29] Ipilimumab/nivolumab/sasanlimabPolyarthritis: 2 case reports [J].

Reactions Weekly, 2023, 1938 (1) :766-766

[30] Ipilimumab/nivolumab/pembrolizumabColitis: 2 case reports [J].

Reactions Weekly, 2020, 1808 (1) :161-161

← 1 2 3 4 5 →